Avatar
Pin82sack

0 Following 0 Followers
1
Ersus host disease, or other abdominal syndromes including cholecystitis, cholangitis, appendicitis need to be ruled out. The management of neutropenic enterocolitis has evolved over the years as clinical experience has grown. Recent studies have reported the success of conservative treatment in most patients. Surgical intervention is now reserved for selected cases of neutropenic enterocolitis ba
1
Eared not to be influenced. In ICU, in a retrospective study of 28 neutropenic patients who received G-CSF compared to 33 patients who did notZafrani and Azoulay BMC Infectious Diseases 2014, 14:512 http://www.biomedcentral.com/1471-2334/14/Page 6 ofreceived G-CSF, Gruson et al. did not found any difference in terms of clinical outcome and occurrence of nosocomial infections [56]. Moreover, as men
1
Eared not to be influenced. In ICU, in a retrospective study of 28 neutropenic patients who received G-CSF compared to 33 patients who did notZafrani and Azoulay BMC Infectious Diseases 2014, 14:512 http://www.biomedcentral.com/1471-2334/14/Page 6 ofreceived G-CSF, Gruson et al. did not found any difference in terms of clinical outcome and occurrence of nosocomial infections [56]. Moreover, as men
1
M the infectious diseases working party of the German Society of Hematology and Oncology [10] for the management of sepsis in neutropenic patient recommend the use of norepinephrine as the drug of choice if a sufficient mean arterial pressure (> 65 mmHg) cannot be achieved by fluid resuscitation, associated with dobutamine in case of sepsis-related myocardial depression . Moreover, D. Schnell and
1
Ithout malignancy [53].Non anti-infectious agentsG-CSF and GM-CSFHaemopoietic growth factors, such as granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been assessed in several clinical trials [54,55]. The known effect of G-CSF and GM-CSF in increasing the number of circulating neutrophil granulocytes was the rationale for clinical stud
1
Ithout malignancy [53].Non anti-infectious agentsG-CSF and GM-CSFHaemopoietic growth factors, such as granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been assessed in several clinical trials [54,55]. The known effect of G-CSF and GM-CSF in increasing the number of circulating neutrophil granulocytes was the rationale for clinical stud
1
Ithout malignancy [53].Non anti-infectious agentsG-CSF and GM-CSFHaemopoietic growth factors, such as granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been assessed in several clinical trials [54,55]. The known effect of G-CSF and GM-CSF in increasing the number of circulating neutrophil granulocytes was the rationale for clinical stud
1
Ithout malignancy [53].Non anti-infectious agentsG-CSF and GM-CSFHaemopoietic growth factors, such as granulocyte colonystimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been assessed in several clinical trials [54,55]. The known effect of G-CSF and GM-CSF in increasing the number of circulating neutrophil granulocytes was the rationale for clinical stud